Exvade Biosciencetm, a clinical-stage neuro-oncology company advancing a breakthrough platform for treating aggressive brain cancers, today highlighted ongoing enrollment in a Phase 1 clinical trial ...
Introduction After the WHO prequalified the first vaccine against mpox, we aimed to identify the influence of vaccine ...
VANCOUVER, BC, Jan. 6, 2026 /PRNewswire/ - GoldMining Inc. (the "Company" or "GoldMining") (TSX: GOLD) (NYSE American: GLDG) is pleased to report additional assay results from the 2025 RC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback